Startup profile · funding coverage
Nava Therapeutics
Biotech developing next-generation lipid nanoparticle delivery systems.
Stage
series a
Status
private
Coverage
full
Why Nava Therapeutics is interesting
Stealth LNP platform play — a16z participated in an $89M Series A (2024) alongside GV, Versant, and F-Prime as RNA delivery remains a bottleneck.
Key facts
- Series A (2024): $89M with a16z, GV, F-Prime, Versant among investors (Endpoints News)
- Co-investors not in VCT directory: GV, Versant Ventures, Readout Capital
Investors in our directory
Funds linked from Nava Therapeutics's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences Healthtech
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Nava Therapeutics's financing or category context.
Last updated: 2026-07-24